-+ 0.00%
-+ 0.00%
-+ 0.00%

Coya Therapeutics completes enrollment in Phase 2/3 ALSTARS trial of COYA 302 in ALS

PUBT·10/05/2026 12:05:24
Listen to the news
Coya Therapeutics completes enrollment in Phase 2/3 ALSTARS trial of COYA 302 in ALS
  • Coya Therapeutics completed enrollment of 120 participants in its Phase 2/3 ALSTARS trial of COYA 302 in ALS.
  • Results have not been presented; topline data from the double-blind treatment phase are expected in early Q2 2027.
  • The study aims to show whether the therapy can slow disease progression in people living with ALS.
  • COYA 302 holds FDA Fast Track status, supporting a faster development and review pathway if the data are positive.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261005528519) on October 05, 2026, and is solely responsible for the information contained therein.